Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mylan CEO Heather Bresch On How Mylan Is Different Than Teva

Executive Summary

CEO Heather Bresch talked to Scrip about how she will navigate the company through what has become a rough period for the US generic drug market and validation on complex generics and biosimilars.

Advertisement

Related Content

Generic Drug Sector Struggles Even As The Need For Cheaper Drugs Grows
Generic Drug Sector Struggles Even As The Need For Cheaper Drugs Grows
J.P. Morgan Notebook Day 1: Tax Reform At Last, Allergan's Job Cuts, Teva Turnaround, Biogen's Cash, And Getting FDA-Friendly
Schultz Swings The Cleaver At Teva, Cutting 25% Of The Workforce
Mylan Insists Complex Generics Strategy Is Poised To Deliver
Neulasta Is 4-0 Versus Biosimilars Now That Mylan Has A CRL From FDA
Are Theravance And Mylan's US COPD Chances Bigger Than First Thought?
Generic Manufacturers Try To Up Their Game As US Pressure Persists
Mylan Clears Runway For US Herceptin Biosimilar Launch
EpiPen's Swollen Price May Trigger Patient Assistance Program Probes

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100223

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel